Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia.
Maraninchi D, Vey N, Viens P, Stoppa AM, Archimbaud E, Attal M, Baume D, Bouabdallah R, Demeoq F, Fleury J, Michallet M, Olive D, Reiffers J, Sainty D, Tabilio A, Tiberghien P, Brandely M, Hercend T, Blaise D. Maraninchi D, et al. Leuk Lymphoma. 1998 Oct;31(3-4):343-9. doi: 10.3109/10428199809059227. Leuk Lymphoma. 1998. PMID: 9869198 Clinical Trial.
Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study.
Reiffers J, Stoppa AM, Attal M, Michallet M, Marit G, Blaise D, Huguet F, Corront B, Cony-Makhoul P, Gastaut JA, Laurent G, Molina L, Broustet A, Maraninchi D, Pris J, Hollard D, Faberes C. Reiffers J, et al. Among authors: maraninchi d. Leukemia. 1996 Dec;10(12):1874-82. Leukemia. 1996. PMID: 8946925 Clinical Trial.
The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission.
Blaise D, Attal M, Pico JL, Reiffers J, Stoppa AM, Bellanger C, Molina L, Nedellec G, Vernant JP, Legros M, Gabus R, Huguet F, Brandely M, Hercend T, Olive D, Maraninchi D. Blaise D, et al. Among authors: maraninchi d. Leuk Lymphoma. 1997 May;25(5-6):469-78. doi: 10.3109/10428199709039034. Leuk Lymphoma. 1997. PMID: 9250817 Clinical Trial.
Anti-GM-CSF monoclonal antibody therapy for refractory acute leukemia.
Bouabdallah R, Olive D, Meyer P, Lopez M, Sainty D, Hirn M, Mannoni P, Fougereau E, Gastaut JA, Maraninchi D. Bouabdallah R, et al. Among authors: maraninchi d. Leuk Lymphoma. 1998 Aug;30(5-6):539-49. doi: 10.3109/10428199809057566. Leuk Lymphoma. 1998. PMID: 9711916 Clinical Trial.
Second neoplasms following high-dose chemotherapy and autologous stem cell transplantation for malignant lymphomas: a report of six cases in a cohort of 171 patients from a single institution.
Oddou S, Vey N, Viens P, Bardou VJ, Faucher C, Stoppa AM, Chabannon C, Camerlo J, Bouabdallah R, Gastaut JA, Maraninchi D, Blaise D. Oddou S, et al. Among authors: maraninchi d. Leuk Lymphoma. 1998 Sep;31(1-2):187-94. doi: 10.3109/10428199809057598. Leuk Lymphoma. 1998. PMID: 9720728 Clinical Trial.
Interleukin 2 in the treatment of acute leukemia.
Blaise D, Maraninchi D. Blaise D, et al. Among authors: maraninchi d. Leuk Res. 1998 Dec;22(12):1165-70. doi: 10.1016/s0145-2126(98)00115-5. Leuk Res. 1998. PMID: 9922080 Review. No abstract available.
Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high-intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin's lymphoma: an oligocentric report on 42 patients.
Bouabdallah R, Stoppa AM, Rossi JF, Lepeu G, Coso D, Xerri L, Ladaique P, Chabannon C, Blaise D, Bardou VJ, Alzieu C, Gastaut JA, Maraninchi D. Bouabdallah R, et al. Among authors: maraninchi d. Leukemia. 1999 Jun;13(6):950-6. doi: 10.1038/sj.leu.2401444. Leukemia. 1999. PMID: 10360385
314 results